Report of Foreign Issuer (6-k)
March 18 2019 - 4:29PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2019
Commission File Number
001-37846
CELLECT
BIOTECHNOLOGY LTD.
(Translation of registrant’s name
into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
Attached hereto as Exhibit 99.1 and incorporated
by reference herein is a press release issued by the Registrant entitled “Cellect Biotechnology Reports Fourth Quarter and
Full Year 2018 Results and Recent Corporate Progress.”
Exhibit
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
Date: March 18, 2019
|
|
Title: Chief Financial Officer
|
2
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Sep 2023 to Sep 2024